Please cite this article in press as: Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014), http://dx. doi. org/10. 1016/j. bbr. 2014. 07. 016ARTICLE IN PRESSG Model BBR 9035 1-22 A. L. Halberstadt / Behavioural Brain Research xxx (2014) xxx-xxx 17 to top-down modulation of visual processing. Cereb Cortex 2007;17(Suppl 1):i125-35. [154] Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, et al. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) 2005;181:496-503. [155] Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, et al. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 2007;321:1054-61. [156] Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 2014;77:200-7. [157] Ettrup A, Holm S, Hansen M, Wasim M, Santini MA, Palner M, et al. Preclinical safety assessment of the 5-HT 2Areceptor agonist PET radioligand [11C]Cimbi-36. Mol Imaging Biol 2013;15:376-83. [158] Parrish JC, Braden MR, Gundy E, Nichols DE. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists. J Neu-rochem 2005;95:1575-84. [159] Leysen JE, Niemegeers CJ, Van Nueten JM, Laduron PM. [3H]Ketanserin (R 41 468), a selective3H-ligand for serotonin 2receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 1982;21:301-14. [160] Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2Areceptors: modulation by novel 5-HT 2A/2C antagonists, D1antagonists and 5-HT 1Aagonists. J Pharmacol Exp Ther 1995;273:101-12. [161] Dursun SM, Handley SL. Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physio-logical conditions. Psychopharmacology (Berl) 1996;128:198-205. [162] Smith RL, Barrett RJ, Sanders-Bush E. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A recep-tor. J Pharmacol Exp Ther 1995;275:1050-7. [163] Fox MA, French HT, Laporte JL, Blackler AR, Murphy DL. The serotonin 5-HT2Areceptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology (Berl) 2009;212:13-23. [164] Dougherty JP, Aloyo VJ. Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice. Psychopharmacology (Berl) 2011;215:581-93. [165] Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81. [166] Halberstadt AL, Koedood L, Powell SB, Geyer MA. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol 2011;25:1548-61. [167] Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) 2010;209:163-74. [168] Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 1994;111:797-802. [169] Wettstein JG, Host M, Hitchcock JM. Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI). Prog Neuropsy-chopharmacol Biol Psychiatry 1999;23:533-44. [170] Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, et al. Modulation of 5-HT 2Areceptor-mediated head-twitch behaviour in the rat by 5-HT 2Creceptor agonists. Pharmacol Biochem Behav 2001;69:643-52. [171] Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, et al. Interaction of 5-HT 2Aand 5-HT 2Creceptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther 2010;335:728-34. [172] Siuciak JA, Chapin DS, Mc Carthy SA, Guanowsky V, Brown J, Chiang P, et al. CP-809,101, a selective 5-HT 2Cagonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007;52:279-90. [173] Canal CE, Booth RG, Morgan D. Support for 5-HT2C receptor functional selec-tivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology 2013;70:112-21. [174] Calcagno E, Invernizzi RW. Strain-dependent serotonin neuron feedback con-trol: role of serotonin 2C receptors. J Neurochem 2010;114:1701-10. [175] Hackler EA, Airey DC, Shannon CC, Sodhi MS, Sanders-Bush E. 5-HT2C receptor RNA editing in the amygdala of C57BL/6J DBA/2J, and BALB/c J mice. Neurosci Res 2006;55:96-104. [176] Burns CM, Chu H, Rueter S, Hutchinson LK, Canton H, Sanders-Bush E, et al. Regulation of serotnon-2C receptor G-protein coupling by RNA editing. Nature 1997;387:303-8. [177] Swerdlow NR, Geyer MA. Using an animal model of deﬁcient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 1998;24:285-301. [178] Sipes TA, Geyer MA. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 1994;33:441-8. [179] Padich RA, Mc Closkey TC, Kehne JH. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 ondisruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology (Berl) 1996;124:107-16. [180] Johansson C, Jackson DM, Zhang J, Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol Biochem Behav 1995;52:649-54. [181] Ouagazzal A, Grottick AJ, Moreau J, Higgins GA. Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological anal-ysis and comparison between two rat strains. Neuropsychopharmacology 2001;25:565-75. [182] Halberstadt AL, Geyer MA. LSD but not lisuride disrupts prepulse inhibi-tion in rats by activating the 5-HT2A receptor. Psychopharmacology (Berl) 2010;208:179-89. [183] Pálenícek T, Balíková M, Bubeníková-Valesová V, Horácek J. Mescaline effects on rat behavior and its time proﬁle in serum and brain tissue after a single subcutaneous dose. Psychopharmacology (Berl) 2008;196:51-62. [184] Pálení ˇcek T, Fujáková M, Brunovsk ´y M, Horá ˇcek J, Gorman I, Balíková M, et al. Behavioral, neurochemical and pharmaco-EEG proﬁles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharma-cology (Berl) 2013;225:75-93. [185] Sipes TE, Geyer MA. DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT 2Aand not by 5-HT 2Creceptors. Behav Pharmacol 1995;6:839-42. [186] Varty GB, Higgins GA. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berl) 1995;122:15-26. [187] Serko A. Im Mescalinrausch. Jahrb Psychiatr Neurol 1913;31:355-66. [188] Hoch P, Cattell JP, Pennes HH. Effects of mescaline and lysergic acid diethy-lamide (d. LSD-25). Am J Psychiatry 1952;108:579-84. [189] Bercel NA, Travis LE, Olinger LB, Dreikurs E. Model psychoses induced by LSD-25 in normals: I. Psychophysiological investigations, with special ref-erence to the mechanism of the paranoid reaction. Arch Gen Psychiatry 1956;76:588-611. [190] Aronson H, Silverstein AB, Klee GD. Inﬂuence of lysergic acid diethylamide (LSD-25) on subjective time. AMA Arch Gen Psychiatry 1959;1:469-72. [191] Kenna JC, Sedman G. The subjective experience of time during lysergic acid diethylamide (LSD-25) intoxication. Psychopharmacologia 1964;5:280-8. [192] Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol 2007;21:50-64. [193] Stubbs DA. Temporal differentiation and a free-operant psychophysical pro-cedure. J Exp Anal Behav 1980;33:167-85. [194] Body S, Chiang TJ, Mobini S, Ho MY, Bradshaw CM, Szabadi E. Effect of 8-OH-DPAT on temporal discrimination following central 5-hydroxytryptamine depletion. Pharmacol Biochem Behav 2002;71:787-93. [195] Body S, Kheramin S, Ho MY, Miranda F, Bradshaw CM, Szabadi E. Effects of a 5-HT2 receptor agonist (5-dimethoxy-4-iodoamphetamine), and antagonist, ketanserin, on the performance of rats on a free-operant timing schedule. Behav Pharmacol 2003;14:599-607. [196] Body S, Cheung TH, Bezzina G, Asgari K, Fone KC, Glennon JC, et al. Effects of d-amphetamine and (5-dimethoxy-4-iodoamphetamine) on timing behavior: interaction between D1 and 5-HT2A receptors. Psychopharmacology (Berl) 2006;189:331-43. [197] Asgari K, Body S, Bak VK, Zhang ZQ, Rickard JF, Glennon JC, et al. Effects of 5-HT2A receptor stimulation on the discrimination of durations by rats. Behav Pharmacol 2006;17:51-9. [198] Hampson CL, Body S, Den Boon FS, Cheung THC, Bezzina G, Langley RW, et al. Comparison of the effects of 2,5-dimethoxy-4-iodoamphetamine and d-amphetamine on the ability of rats to discriminate the durations and inten-sities of light stimuli. Behav Pharmacol 2010;21:11-20. [199] Hughes RN. Chlordiazepoxide modiﬁed exploration in rats. Psychopharma-cologia 1972;24:462-9. [200] Geyer MA, Russo PV, Masten VL. Multivariate assessment of locomotor behav-ior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 1986;25:277-88. [201] Paulus MP, Geyer MA. A temporal and spatial scaling hypothesis for the behav-ioral effects of psychostimulants. Psychopharmacology (Berl) 1991;104:6-16. [202] Adams LM, Geyer MA. Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:121-32. [203] Adams LM, Geyer MA. A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats. Behav Neurosci 1985;99:881-900. [204] Wing LL, Tapson GS, Geyer MA. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl) 1990;100:417-25. [205] Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-Me O-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) 2006;189:319-29. [206] Salvatore S, Hyde RW. Progression of effects of lysergic acid diethylamide (LSD). AMA Arch Neurol Psychiat 1956;2:50-9. [207] Geyer MA, Russo PV, Segal DS, Kuczenski R. Effects of apomorphine and amphetamine on patterns of locomotor and investigatory behavior in rats. Pharmacol Biochem Behav 1987;28:393-9. [208] Mittman SM, Geyer MA. Effects of 5HT-1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psy-chopharmacology (Berl) 1989;98:321-9. 1699 1700170117021703170417051706170717081709171017111712171317141715171617171718171917201721172217231724172517261727172817291730173117321733173417351736173717381739174017411742174317441745174617471748174917501751175217531754175517561757175817591760176117621763176417651766176717681769177017711772177317741775177617771778177917801781178217831784 178517861787178817891790179117921793179417951796179717981799180018011802180318041805180618071808180918101811181218131814181518161817181818191820182118221823182418251826182718281829183018311832183318341835183618371838183918401841184218431844184518461847184818491850185118521853185418551856185718581859186018611862186318641865186618671868